FANJ
SLDB icon

Financial Architects (New Jersey)’s Solid Biosciences SLDB Stock Holding History

Financial Architects (New Jersey)’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-53
Closed -$7K – 1434
2019
Q1 		$7K Buy
+53
New +$13.3K ﹤0.01% 1171

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Financial Architects (New Jersey)'s SLDB Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Solid Biosciences (SLDB) in Q2 2019, closing a stake of 53 shares — an estimated $7K sold.

Financial Architects (New Jersey) first reported a position in SLDB in Q1 2019 and held it in 1 quarter. The position peaked at $7K in Q1 2019. 74 funds tracked by Wall St. Rank hold SLDB as of Q2 2019.

  • Financial Architects (New Jersey) reported no remaining Solid Biosciences position as of Q2 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 53 Solid Biosciences shares in Q2 2019, an estimated $7K.
  • Financial Architects (New Jersey) first reported a position in Solid Biosciences in Q1 2019 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Solid Biosciences position peaked at $7K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.